Eli Lilly and Company logo

Eli Lilly and Company (LLY)

Market Closed
5 Dec, 20:00
NYSE NYSE
$
1,010. 31
-4.18
-0.41%
$
992.01B Market Cap
104.2 P/E Ratio
5.2% Div Yield
1,963,618 Volume
6.64 Eps
$ 1,014.49
Previous Close
Day Range
1,004 1,027.39
Year Range
623.78 1,111.99
Want to track LLY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 60 days
Andreessen Horowitz, Eli Lilly to launch $500 million venture fund

Andreessen Horowitz, Eli Lilly to launch $500 million venture fund

Venture capital firm Andreessen Horowitz said on Friday it was working with Eli Lilly to launch a $500 million venture fund that will be fully funded by the U.S. drugmaker.

Reuters | 11 months ago
Eli Lilly (LLY) Vs Novo Nordisk (NVO): Which is the Best Weight Loss Stock for 2025?

Eli Lilly (LLY) Vs Novo Nordisk (NVO): Which is the Best Weight Loss Stock for 2025?

Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly (LLY) and Novo Nordisk (NVO) stock.

Zacks | 11 months ago
LLY Falls Around 14% in 3 Months: How to Play the Stock

LLY Falls Around 14% in 3 Months: How to Play the Stock

Though Eli Lilly stock looks quite expensive, we suggest investors hold on to it as it still has robust growth prospects.

Zacks | 11 months ago
Top pharmaceutical stocks to buy in 2025

Top pharmaceutical stocks to buy in 2025

Pharmaceutical stocks represent an interesting prospect — while it is incredibly tough to separate the wheat from the chaff, picking a winner early on is more or less a ticket to outsized returns.

Finbold | 11 months ago
Why the Market Dipped But Eli Lilly (LLY) Gained Today

Why the Market Dipped But Eli Lilly (LLY) Gained Today

In the latest trading session, Eli Lilly (LLY) closed at $773.29, marking a +1.07% move from the previous day.

Zacks | 11 months ago
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know

Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know

Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks | 11 months ago
Lilly asks to join lawsuit over compounded versions of its weight-loss drugs

Lilly asks to join lawsuit over compounded versions of its weight-loss drugs

Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug Administration over the agency's decision that Lilly's blockbuster weight-loss and diabetes drugs are no longer in short supply.

Reuters | 11 months ago
5 Large Drug Stocks to Keep An Eye On in the New Year

5 Large Drug Stocks to Keep An Eye On in the New Year

R&D innovation is likely to remain a major focus area in 2025. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), AbbVie (ABBV), AstraZeneca (AZN) and Pfizer (PFE) are worth retaining in one's portfolio.

Zacks | 11 months ago
Lilly and Novo Went Head-to-Head Over Weight-Loss Drugs in 2024. There's a Clear Winner.

Lilly and Novo Went Head-to-Head Over Weight-Loss Drugs in 2024. There's a Clear Winner.

It hasn't been a smooth year for the two pharma giants, but events in the fourth quarter widened the gap between them.

Barrons | 11 months ago
Why Eli Lilly (LLY) Dipped More Than Broader Market Today

Why Eli Lilly (LLY) Dipped More Than Broader Market Today

Eli Lilly (LLY) reachead $773.84 at the closing of the latest trading day, reflecting a -1.19% change compared to its last close.

Zacks | 11 months ago
Will This Major Pharmaceutical Stock Announce a Stock Split in 2025?

Will This Major Pharmaceutical Stock Announce a Stock Split in 2025?

Stocks splits have been a huge market theme in 2024, with big names across industries, from technology giant Nvidia to consumer stock Walmart completing such operations. Companies often launch this move after a long period of gains as a way to make their stock price more accessible to a wide range of investors.

Fool | 11 months ago
Billionaire Philippe Laffont Is Selling Artificial Intelligence Champion Nvidia and Piling Into These Two Industry Leaders

Billionaire Philippe Laffont Is Selling Artificial Intelligence Champion Nvidia and Piling Into These Two Industry Leaders

If you're looking for top stocks, there's no need to reinvent the wheel. The Securities and Exchange Commission makes it a breeze to follow the world's greatest investors.

Fool | 11 months ago
Loading...
Load More